Previous 10 | Next 10 |
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its second quarter 2020 update and financial results on Tuesday, August 4 at 4:30 p.m. ET. To participate in the Webcast/Conference call, please note there is a new pre-registration proces...
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
NEW YORK , May 6, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening on Tuesday, May 12 : DexCom Inc. (NASD:DXCM) will replace Allergan plc (NY...
DexCom (NASDAQ: DXCM ) is up 4.3% postmarket as it's making a move to the S&P 500 , to replace Allergan (NYSE: AGN ) - set to be acquired by AbbVie. More news on: DexCom, Inc., Allergan plc, salesforce.com, inc., Consumer stocks news, Financial stocks news, Tech stocks news, Stocks ...
Acorda Therapeutics, Inc. (ACOR) Q1 2020 Earnings Conference Call May 05, 2020, 16:30 ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Conference Call Participants Michael Yee - Jefferies Alexander ...
Acorda Therapeutics (NASDAQ: ACOR ): Q1 Non-GAAP EPS of -$0.51 misses by $0.10 ; GAAP EPS of -$0.14 beats by $0.31 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
INBRIJA ® (levodopa inhalation powder) 1Q 2020 net revenue of $4.4 million AMPYRA ® (dalfampridine) 1Q 2020 net revenue of $20.1 million Reiterates 2020 AMPYRA net revenue guidance and operating expense guidance Withdraws 2020 INBRIJA net revenue guidance due to the...
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (inter...
Acorda Therapeutics ( ACOR ) is in a better position after addressing the convertible note overhang last year. In my previous article , I noted the company is uninvestable due to this substantial financing overhang as the company lacked the cash to pay the noteholders in 2021 and the conversi...
Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
News, Short Squeeze, Breakout and More Instantly...
Acorda Therapeutics Inc. Company Name:
ACOR Stock Symbol:
NASDAQ Market:
Acorda Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 11.3% to $0.2025 on volume of 40,515,259 shares Rallybio Corporation (RLYB) rose 80.4% to $2.9401 on volume of 39,492,767 shares Trio Petroleum Corp. (TPET) rose 36.3% to $0.2499 on volume of 3...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 28.8% to $0.0515 on volume of 62,068,605 shares Laser Photonics Corporation (LASE) rose 172.7% to $3.9 on volume of 54,588,758 shares WiSA Technologies Inc. (WISA) fell 6.1% to $0.0217 on volume of 2...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announc...